Biomarin Pharmaceutical (WBO:BMRN) Cash-to-Debt : 0.95 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biomarin Pharmaceutical's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.95.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biomarin Pharmaceutical couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Biomarin Pharmaceutical's Cash-to-Debt or its related term are showing as below:

WBO:BMRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68 Med: 1.03 Max: 1.54
Current: 0.95

During the past 13 years, Biomarin Pharmaceutical's highest Cash to Debt Ratio was 1.54. The lowest was 0.68. And the median was 1.03.

WBO:BMRN's Cash-to-Debt is ranked worse than
77.89% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs WBO:BMRN: 0.95

Biomarin Pharmaceutical Cash-to-Debt Historical Data

The historical data trend for Biomarin Pharmaceutical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biomarin Pharmaceutical Cash-to-Debt Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.88

0.98

0.93

1.18

0.98

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															1.05	1.07	1.03	0.98	0.95

Competitive Comparison of Biomarin Pharmaceutical's Cash-to-Debt

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cash-to-Debt falls into.

Biomarin Pharmaceutical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biomarin Pharmaceutical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	984.684	/	(460.936	+	543.868)
	=	0.98

Biomarin Pharmaceutical's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	962.854	/	(462.697	+	546.117)
	=	0.95

Biomarin Pharmaceutical (WBO:BMRN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biomarin Pharmaceutical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (WBO:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.